DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kelley RK, Sangro B, Harris WP. et al.
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
J Clin Oncol 2020;
38: 4508-4508
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.